Abstract
Genetic variations in drug-induced liver injury (DILI): resolving the puzzle
Highlights
There are discrepancies in the findings and many studies are based on small cohorts and subsequently insufficient to confirm a prominent association between genetic variability in drug metabolism and the risk of drug-induced liver injury (DILI)
A range of studies have identified a number of genetic variants in drug metabolism Phase I, II, and III genes, including cytochrome P450 (CYP) 2E1, N-acetyltransferase 2, UDP-glucuronosyltransferase 2B7, glutathione S-transferase M1/T1, ABCB11, and ABCC2, that enhance DILI susceptibility (Andrade et al, 2009; Agundez et al, 2011)
There are discrepancies in the findings and many studies are based on small cohorts and subsequently insufficient to confirm a prominent association between genetic variability in drug metabolism and the risk of DILI
Summary
There are discrepancies in the findings and many studies are based on small cohorts and subsequently insufficient to confirm a prominent association between genetic variability in drug metabolism and the risk of DILI. A range of studies have identified a number of genetic variants in drug metabolism Phase I, II, and III genes, including cytochrome P450 (CYP) 2E1, N-acetyltransferase 2, UDP-glucuronosyltransferase 2B7, glutathione S-transferase M1/T1, ABCB11, and ABCC2, that enhance DILI susceptibility (Andrade et al, 2009; Agundez et al, 2011).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
